Sign in / Join Now
ETFs & Funds
Stopped out of $
at an average of $8. May look to re-establish trade later
I am long EXCEL since it was at $5 and also wrote puts on it. This will be a multi bagger.
Add a reply...
Latest StockTalks »
people get EXEL breaking news and analysis by email alert.
Get email alerts on EXEL »
Get latest price
From other sites
Update On Dispute Between Exelixis And Genentech, A Member Of The Roche Group
at TheStreet (Jan 9, 2017)
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
at TheStreet (Jan 3, 2017)
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
at Zacks.com (Dec 23, 2016)
Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx
at Zacks.com (Dec 22, 2016)
Exelixis And Ipsen Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada
at TheStreet (Dec 21, 2016)